cFLIP-L Inhibits p38 MAPK Activation

AN ADDITIONAL ANTI-APOPTOTIC MECHANISM IN BILE ACID-MEDIATED APOPTOSIS*

Annette Grambihler, Hajime Higuchi, Steven F. Bronk and Gregory J. Gores {ddagger}

From the Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic, and Foundation, Rochester, Minnesota 55905

Received for publication, March 28, 2003 , and in revised form, May 8, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In cholestasis, toxic bile acids accumulate within the liver inducing hepatocyte apoptosis, which exacerbates liver injury. Although bile acids activate both death receptors and mitogen-activated kinase (MAPK) pathways, the mechanistic link between death receptor signaling and MAPK activation in bile acid apoptosis remains unclear. The aim of this study was to ascertain if MAPKs contribute to bile acid cytotoxicity. Although deoxycholate induced apoptosis and activated all three classic mediators of the MAPK pathways including JNK 1/2, p38, and p42/44, only p38 MAPK inhibition attenuated apoptosis. Suppressing FADD expression with siRNA or employing a caspase inhibitor, zVAD-fmk, did not block p38 MAPK activation suggesting its activation was not death receptor-dependent. Unexpectedly, expression of cFLIP-L in a stably transfected cell line blocked apoptosis and p38 MAPK phosphorylation. Based on these data we postulated a direct effect of cFLIP on p38 MAPK activation. The nonphosphorylated but not the phosphorylated/active form of p38 MAPK co-immunoprecipitated with cFLIP-L. In reverse immunoprecipitation experiments, cFLIP-L long but not cFLIP-S co-immunoprecipitate with p38 MAPK. In conclusion, these data suggest that cFLIP-L exerts its anti-apoptotic activity, in part, by inhibiting p38 MAPK activation, an additional anti-apoptotic effect for this protein.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
In virtually all human liver diseases, hepatocytes undergo cell death by apoptosis (1). This is also true for cholestatic liver diseases, pathophysiologic syndromes characterized by impaired hepatocellular secretion of bile acids into bile. In cholestasis, the intracellular accumulation of toxic bile acids within hepatocytes promotes cellular injury and the subsequent development of hepatic cirrhosis and liver failure (2). Numerous studies have shown that bile acids mediate their cytotoxicity by inducing hepatocellular apoptosis (36). Bile acid-mediated apoptosis is, in part, death receptor-dependent. For example, toxic bile acids trigger oligomerization of Fas in a ligand-independent manner by promoting trafficking of intracellular Fas to the plasma membrane (7). In the absence of Fas, toxic bile acids enhance DR5/TRAIL-R2 expression and aggregation, also promoting a death receptor-dependent apoptosis (8). The in vivo relevance of these in vitro observations has been amply demonstrated (911). Insight into the mechanisms of bile acid-associated death receptor signaling is, therefore, of scientific and potential therapeutic relevance.

In addition to activating death receptors, bile acids also activate mitogen-activated protein kinases (MAPKs)1 (1219). At present three major groups of MAPKs are known: the classic p42/44 MAPK or extracellular receptor kinase 1 and 2, c-Jun-N-terminal kinase (JNK 1/2), and p38 MAPK. The p42/44 MAPKs are mainly involved in cell survival and proliferation pathways, and their inhibition has been shown to potentiate bile acid-induced apoptosis in hepatocytes (4, 20). In contrast, prolonged stimulation of p38 MAPK or JNK 1/2 promotes apoptosis in a variety of other models (21, 22). Several upstream kinases have been implicated in the activation of the p38 MAPK and JNK 1/2 including apoptosis signaling kinase-1 which appears to activate both p38 MAPK and JNK 1/2, MKK 3/6 which activates p38 MAPK, and MKK 4/7 which activates JNK 1/2 (23). Although both bile acids and death receptors, such as Fas and tumor necrosis factor receptor-1, have been shown to activate MAPK pathways, it is still unknown whether bile acid MAPK activation occurs downstream of death receptor-mediated caspase activation or by a separate, death receptor-independent pathway. Moreover, the mechanistic contribution of MAPK activation in bile acid-mediated apoptosis remains unclear.

The role of death receptor caspase activation in bile acid-induced MAPK activation can be potentially delineated by inhibiting death receptor cytotoxic signaling. Death receptor-dependent caspase activation can be disrupted by interrupting formation and function of the death inducing signaling complex (DISC). Once aggregated, death receptors, such as Fas and DR5/TRAIL-R2, recruit the cytoplasmic adapter protein FADD (Fas-associated death domain) and initiator caspases, procaspase 8 and 10 to the receptor complex (2426). Once recruited to the DISC, these procaspases undergo autocatalytic processing within the DISC (27, 28). This DISC formation and function can be disrupted by inhibiting FADD expression or employing a dominant negative FADD, by blocking the activation of initiator caspases with pharmacologic caspase inhibitors, or by augmenting expression of FLICE inhibitory protein (cFLIP, also called Flame-1/I-FLICE/Casper/CASH/MRIT/CLARP/Usurpin) (2936). cFLIP inhibits death receptor cytotoxic signaling by regulating both recruitment and processing of procaspases within the DISC (3739). Interrupting DISC function should help clarify if bile acid-mediated activation of MAPK is death receptor/FADD/caspase-dependent or occurs via a parallel process.

The overall objective of this study was to test the hypothesis that MAPK activation occurs and contributes to bile acid-mediated apoptosis. To address this hypothesis, the following two questions were formulated: (i) do inhibitors of p38 MAPK, p42/44 MAPK, and/or JNK 1/2 attenuate bile acid-induced apoptosis and (ii) is MAPK activation by bile acids because of death receptor-mediated caspase activation? We employed deoxycholate (DC) for these studies as it is a potent bile acid apoptogen and strongly activates MAPK pathways (4, 40). The results indicate that p38 MAPK contributes to bile acid cytotoxicity, likely by a death receptor-independent pathway. Unexpectedly, cFLIP was observed to co-immunoprecipitate with the unphosphorylated form of p38 MAPK, suggesting that this protein prevents p38 MAPK activation, thereby protecting cells from bile acid-induced apoptosis. These studies suggest a new anti-apoptotic mechanism for cFLIP, namely inhibition of p38 MAPK activation.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Materials—Reagents were purchased from the following suppliers: deoxycholate and Sepharose-CL 4B were obtained from Sigma; 4',6-diamidino-2-phenylindolehydrochloride (DAPI) was from Molecular Probes Inc. (Eugene, OR); zVAD-fmk from Enzyme Systems Products (Livermore, CA); the JNK 1/2-inhibitor SP600125 was from Biomol Research Laboratories (Plymouth Meeting, PA), the p42/44 MAPK-inhibitor UO126 and the p38 MAPK-inhibitor SB203580 were from Calbiochem (San Diego, CA); rat monoclonal (IgG2a) anti-cFLIP and mouse monoclonal (IgG2a) anti-TNF-R1 were from Alexis (San Diego, CA); mouse monoclonal (IgG1) anti-FADD was from Transduction Laboratories (San Diego, CA); rabbit anti-total p38 MAPK and goat polyclonal anti-actin were from Santa Cruz (Santa Cruz, CA); rabbit anti-ACTIVE p38 MAPK, rabbit anti-ACTIVE JNK 1/2, and anti-ACTIVE p42/44 MAPK were purchased from Promega; horseradish peroxidase-conjugated anti-goat Igs, rabbit Igs, rat Igs, and mouse Igs were from BIOSOURCE (Camarillo, CA); protein G-Sepharose was from Zymed Laboratories, Inc. (San Francisco, CA).

Generation of HuH-cFLIP Cell Lines and Cell Culture—HuH7 cells, a human hepatocellular carcinoma cell line, were stably transfected with cFLIP-L. An expression vector for human cFLIP-L, cDNA cloned into the multiple cloning site of a pcDNA3 plasmid, was a gift from Dr. E. Alnemri (Thomas Jefferson University, Philadelphia, PA). HuH7 cells were cultured until 30% subconfluent in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Transfection with the cFLIP pcDNA3 plasmid was performed using LipofectAMINE (Invitrogen) according to the manufacturer's instructions. Stably transfected clones were selected in medium containing 1200 mg/ml G418. Individual clones were subcloned and screened for cFLIP overexpression by immunoblot analysis. Established clones were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100,000 units/liter penicillin, 100 mg/liter streptomycin, 100 mg/liter gentamycin, and 1200 mg/liter G418. Before treatment with deoxycholate or other compounds, cells were cultured in the same medium without serum for 16–48 h, reagents were then added to the media according to the experimental protocol.

Plasmids and Transfection—The plasmid for mutated MKK3 (MKK3(ala) in pRC/RSV) was a gift from Dr. R. Davis (University of Massachusetts, Worcester, MA) and has been previously described (41). The expression vector MKK3(ala) in pRC/RSV encodes a mutant MAPK kinase 3 which acts as a dominant negative and prevents p38 MAPK activation. The GFP expression vector pEGFP-N1 was purchased from Clontech. HuH7 cells were transiently transfected using Lipofect-AMINE as previously described (19). In brief, cells grown in 12-well dishes were transfected by adding 0.5 ml of Opti-MEM I containing 3 µl of LipofectAMINE (Invitrogen), 4 µl of PLUSReagent (Invitrogen), and 0.8 µg of DNA each, MKK3(ala) (0.6 µg) and pEGFP-N1 (0.2 µg). Control cells were transfected with 0.8 µg of pEGFP-N1. The cells were incubated in the above mixture for 5 h at 37 °C in a 5% CO2, 95% air incubator. After this incubation, the media was changed to Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Twenty-four hours later, the cells were incubated with deoxycholate in serum-free media for 12 h. Transfected cells were identified by their green fluorescence, and the transfection efficiency was ~30–40% for all plasmids as estimated by the percentage of cells expressing GFP. The rate of apoptosis in transfected cells was evaluated by 4',6-diamidino-2phenylindolehydrochloride (DAPI) staining and counting of apoptotic nuclei under fluorescent microscopy as described below.

Short Interfering RNA and Transfection—Short interfering RNA (siRNA), a specific double-stranded 21-nucleotide RNA sequence homologous to the target gene, was used to silence FADD expression. siRNA for FADD was designed and synthesized using the software2 and SilencerTM siRNA construction kit from Ambion (Austin, TX) according to the manufacturer's instructions. The sequence of the double stranded RNA employed to block FADD expression in the current experiments is AATGCGTTCTCCTTCTCTGTGCCTGTC. Inhibition of FADD protein expression was assessed by immunoblot analysis following transfection of HuH7 cells with FADD-siRNA. Briefly, HuH7 cells were grown in 10-cm dishes and transiently transfected with 20 nM siRNA using 8 µl of siPORT Amine (Ambion Inc.) in a total transfection volume of 0.5 ml of Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. After incubation at 37 °C, 5% CO2 for 5 h, 1.5 ml of normal growth media was added. Before incubation with deoxycholate cells were serum starved for 24 h. Samples were then prepared and analyzed for apoptosis or by immunoblot as described below.

Quantitation of Apoptosis—Apoptosis was quantified by assessing the characteristic nuclear changes of apoptosis (i.e. chromatin condensation and nuclear fragmentation) using the nuclear binding dye DAPI and fluorescence microscopy.

Measurement of Intracellular Caspase Activity—HuH7 and HuH-cFLIP cells were grown on 35-mm glass-bottom microwell dishes (Mattek Corp., Ashland, MA) at a density of 1000 cells/dish. Intracellular total caspase activity was measured in single cells using the fluorophore-tagged pancaspase inhibitor carboxyfluorescein-VAD-fmk (FAM-VAD-fmk, CaspaTag; Intergen Co., Purchase, NY) according to the manufacturer's instructions, and fluorescence was evaluated with an inverted fluorescence microscope (Axiovert 35M; Carl Zeiss Inc., Thornwood, NY) using excitation and emission wavelengths of 490 and 520 nm, respectively. Digital images were captured and then analyzed and quantitated using fluorescent imaging software (Metafluor Imaging System; Universal Imaging Corp., West Chester, PA). Fluorescence intensity for individual cells was quantitated and the average fluorescent intensity determined for 100 cells per group.

Immunoblot Analysis—Cells were lysed by incubation on ice for 30 min in lysis buffer containing 20 mM Tris-HCl (pH 7.5), 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM Na3VO4, 50 mM NaF, 100 mM phenylmethylsulfonyl fluoride, and a commercial protease inhibitor mixture (Complete-Mini Protease Inhibitor Mixture; Roche Diagnostics). After insoluble debris was pelleted by centrifugation at 14,000 x g for 15 min at 4 °C, the supernatants were collected. Samples were resolved by 12% SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membrane, and blotted with appropriate antibodies at a dilution of 1:1000. Peroxidase-conjugated secondary antibodies (BIOSOURCE International, Camarillo, CA.) were used at a dilution of 1:2000 to 1:10000. Bound antibody was visualized using chemiluminescent substrate (ECL; Amersham Biosciences) and exposed to Kodak X-Omat film. Primary antibodies used included anti-p38 MAPK, anti-active p38 MAPK, anti-active JNK 1/2, anti-active p42/44 MAPK, anti-cFLIP, and anti-FADD.

Immunoprecipitation Assay—HuH7 cells in 10-cm dishes were incubated with deoxycholate (100 µM) for 4 h. Cells were lysed with the lysis buffer as described above (immunoblot analysis). After the protein concentration in the extracts was determined, cell lysates containing 4 mg of protein in 0.5 ml of lysis buffer were precleared by incubation with 30 µl of Sepharose-CL 4B for 3 h at 4 °C. cFLIP and p38 protein were immunoprecipitated by incubation with rat monoclonal (IgG2a) anti-cFLIP (Alexis) antibody (5 µg) or rabbit anti-total p38 MAPK antibody (Santa Cruz) and protein G-Sepharose (30 µl) for an additional 2hat4 °C. Immune complexes were pelleted by centrifugation for 5 min at 14,000 x g, washed five times with lysis buffer, and released from the beads by boiling for 5 min in SDS sample buffer. Samples were resolved by SDS-PAGE, and immunoblot analysis was performed as described above.

Statistical Analysis—All data represent at least three independent experiments and are expressed as the mean ± S.D. unless otherwise indicated. Differences between groups were compared using analysis of variance for repeated measures and a post-hoc Bonferroni test to correct for multiple comparisons.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
p38 MAPK Is Phosphorylated and Contributes to Apoptosis following DC Treatment of HuH-7 Cells—Initially, the effect of DC on MAPK activation in HuH-7 cells was examined. As has been observed in other liver cell types, DC (100 µM) treatment of HuH-7 cells resulted in phosphorylation and, therefore, activation of all three MAPKs including JNK 1/2, p38 MAPK, and p42/44 MAPK (Fig. 1A). Next, the potential contribution of these MAPKs in DC-induced apoptosis was ascertained by employing selective pharmacologic inhibitors for JNK 1/2, p38 MAPK, and p42/44 MAPK. Neither the JNK 1/2 inhibitor SP600125 (10 to 20 µM) nor the p42/44 MAPK inhibitor UO126 (10 to 20 µM) reduced DC-mediated apoptosis (Fig. 1B). In contrast, the p38 MAPK inhibitor SB203580 (20 µM) significantly attenuated DC-induced apoptosis. To further confirm a role for p38 MAPK in bile acid-mediated apoptosis, we blocked p38 expression using a dominant negative MKK3, an upstream activator of p38 MAPK (42). Transient transfection of HuH-7 cells with dominant negative MKK3 inhibited DC-induced apoptosis (Fig. 1C). Collectively, these data implicate a role for p38 MAPK, but not JNK 1/2 or p42/44 MAPK, in DC-induced apoptosis.



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 1.
p38 MAPK is phosphorylated and contributes to apoptosis following DC treatment of HUH-7 cells. A, HuH7 cells were incubated with deoxycholic acid at a concentration of 100 µM for0to6h, and whole cell lysates containing 30 µg of protein were subjected to SDS-PAGE and immunoblot analysis using phospho-specific antibodies for activated p42/44 MAPK, JNK 1/2, and p38 MAPK (p-p42/44, p-JNK 1/2, p-p38). Representative results of at least three different experiments are depicted. In HuH7 cells, deoxycholate activates the mitogen-activated protein kinases p42/44 MAPK, JNK 1/2, and p38 MAPK in a time-dependent manner. B, HuH7 cells were incubated with 100 µM deoxycholate for 10 h with or without the p42/44 MAPK-inhibitor UO126 (20 µM), the JNK 1/2-inhibitor SP600125 (20 µM), or the p38 MAPK-inhibitor SB203580 (20 µM). Apoptosis was evaluated by DAPI staining and fluorescence microscopy. All data were expressed as mean ± S.D. from three individual experiments and compared with the maximum rate of apoptosis achieved by bile acid treatment alone. Of the three different pharmacologic MAPK inhibitors used only the specific p38 MAPK inhibitor SB203580 caused a significant attenuation of bile acid-induced apoptosis (p < 0.01). C, HuH7 cells were co-transfected with an expression vector for dominant-negative MKK3 and with a GFP expression vector using LipofectAMINE and PLUSReagent (Invitrogen) according to the manufacturer's instructions. Control cells were transfected with GFP expression vector alone. In all experiments, 24 h after transfection cells were incubated with deoxycholate at the indicated concentrations for 10 h, and the rate of apoptosis in GFP expressing cells was evaluated by DAPI staining and fluorescence microscopy. All data are expressed as mean ± S.D. from three individual experiments. Transfection with dnMKK3 significantly inhibited DC-induced apoptosis in HuH7 cells (p < 0.01).

 

Enhanced cFLIP Expression Prevents p38 MAPK Phosphorylation and Apoptosis following DC Treatment of HuH7 Cells—Having demonstrated that p38 MAPK contributes to bile acid-induced apoptosis, the relationship between p38 MAPK and bile acid-associated cytotoxic death receptor signaling was examined. The HuH7 cells employed for these studies express TRAIL receptors-1 and -2, tumor necrosis factor receptor-1, but not Fas (8, 43, 44). TRAIL does not activate p38 MAPK in these cells (data not shown). Next, we employed a blocking antibody for TNF-R1 to abrogate signaling via this death receptor. Whereas the antibody did strongly inhibit TNF-{alpha}-induced p38 phosphorylation, p38 activation after DC treatment was not reduced (Fig. 2), indicating that activation of TNF-R1 by bile acid was not responsible for DC-mediated activation of this MAPK. Death receptor signaling was further perturbed using the pharmacologic pancaspase inhibitor zVAD-fmk, FADD-specific siRNA to knock down FADD expression, and enhanced cFLIP-L expression in a stably transfected cell line. Neither zVAD-fmk nor siRNA-mediated reduction in FADD expression reduced DC-associated p38 MAPK phosphorylation (Fig. 3, A and B). The decrease in FADD expression after transfection with FADD-siRNA was sufficient to inhibit TRAIL-mediated apoptosis in HuH7 cells (Fig. 3C). In contrast, in a cFLIP-L stably transfected HuH7 cell line, termed HuH-cFLIP (Fig. 4A), DC-induced p38 MAPK phosphorylation was attenuated (Fig. 4B). The effect was specific for p38 MAPK, as JNK 1/2 and p42/44 MAPK activation was not reduced. cFLIP expressing clones were also resistant to DC-mediated apoptosis, as assessed by morphological criteria and total caspase activity (Fig. 5, A and B). The discordance between the effects of cFLIP-L on blocking p38 MAPK phosphorylation and the failure of the caspase inhibitor and attenuated FADD expression to prevent this signaling event suggests that cFLIP may prevent p38 MAPK activation by a FADD/caspase-independent process.



View larger version (67K):
[in this window]
[in a new window]
 
FIG. 2.
Activation of p38 by DC is not mediated via TNF-R1. A, HuH7 cells were incubated with DC (100 µM) with or without a blocking antibody for TNF-R1 (15 µg/ml) for 4 h. Whole cell lysates containing 30 µg of protein were subjected to SDS-PAGE and immunoblot using antibodies for activated and total p38 MAPK (phospho- and total p38). Representative results of at least three different experiments are depicted. DC-mediated p38 MAPK phosphorylation was not inhibited by additional treatment with anti-TNF-R1-antibody. B, under the same conditions as described above for panel A, the TNF-R1-antibody did reduce p38 activation following treatment of HuH7 cells with 30 ng/ml TNF-{alpha}.

 


View larger version (35K):
[in this window]
[in a new window]
 
FIG. 3.
DC-mediated activation of p38 MAPK is caspase- and FADD-independent. A, HuH7 cells were incubated with DC (100 µM) with or without the pancaspase inhibitor zVAD-fmk (75 µM) for 4 h. Activation of p38 was assessed by immunoblot as described above. Representative results of at least three different experiments are depicted. DC-mediated p38 MAPK phosphorylation was not inhibited by zVAD-fmk. B, HuH7 cells were transfected with FADD-siRNA and incubated with 100 µM deoxycholate for 4 h. Activated and total p38 were analyzed by immunoblot using whole cell lysates containing 30 µg of protein. Representative results of at least three different experiments are depicted. DC-mediated p38 MAPK phosphorylation was not inhibited by silencing FADD expression. C, suppression of FADD protein expression and death receptor-mediated apoptosis by FADD-siRNA. After transfection of HuH7 cells with FADD-siRNA, an immunoblot for FADD and {beta}-actin was performed to show that FADD-siRNA efficiently suppressed the expression of FADD protein. Apoptosis was evaluated after treatment of transfected cells with TRAIL for 10 h by DAPI and fluorescence microscopy. All data are expressed as mean ± S.D. from three individual experiments. TRAIL-induced apoptosis was significantly reduced in cells transfected with FADD-siRNA (p < 0.001).

 


View larger version (77K):
[in this window]
[in a new window]
 
FIG. 4.
cFLIP overexpression prevents p38 MAPK phosphorylation. A, HuH7 cells were stably transfected with a cFLIP expression vector as described under "Experimental Procedures." Immunoblot for cFLIP and {beta}-actin was performed showing enhanced expression of cFLIP-L in transfected cells as compared with the parent cell line. B, HuH7 and HuH-cFLIP cells were incubated with 100 µM DC for 4 h and the activation levels of p42/44-MAPK, JNK 1/2, and p38-MAPK were evaluated by SDS-PAGE and immunoblot using phospho-specific antibodies as described above. Representative results of at least three different experiments are depicted. In HUH-cFLIP cells the bile acid-mediated activation of p38 MAPK was strongly inhibited as compared with HuH7 cells, whereas no significant difference was observed in p42/44 MAPK and JNK 1/2 activation.

 


View larger version (18K):
[in this window]
[in a new window]
 
FIG. 5.
cFLIP overexpression attenuates deoxycholate-induced apoptosis. A, HuH7 and two HuH clones stably transfected with cFLIP-L were incubated with the indicated doses of deoxycholate for 10 h. The rate of apoptosis was evaluated by DAPI staining and fluorescence microscopy. B, total caspase activity was measured after treatment with 100 µM deoxycholate for 6 h as described under "Experimental Procedures." All data are expressed as mean ± S.D. from three individual experiments. After deoxycholate treatment the morphologic signs of apoptosis were significantly decreased in the HUH clones stably transfected with cFLIP-L versus HUH7 cells (p < 0.001) as was total caspase activity (p < 0.01).

 

cFLIP Interacts with p38 MAPK—Based on the above data we postulated a more direct effect of cFLIP on p38 MAPK phosphorylation/activation, and therefore, determined if these two proteins interact by performing co-immunoprecipitation experiments. To investigate a potential binding interaction between p38 MAPK and cFLIP, HuH-7 cells were serum-starved for 24 h and treated with 100 µM DC for 4 h. Samples were then obtained and immunoprecipitation was performed as described under "Experimental Procedures." Indeed, in nontransfected HuH-7 cells, nonphosphorylated p38 MAPK co-immunoprecipitated with cFLIP-L (Fig. 6A), and cFLIP-L was co-immunoprecipitated with the nonphosphorylated form p38 MAPK (Fig. 6B). Although in untreated HuH7 cells and in cells treated with DC there was no difference in the amount of co-immunoprecipitated proteins, the phosphorylated/active form of p38 MAPK was never identified in the immune complexes suggesting that the cFLIP may participate in a protein-protein interaction only with the inactive form of this kinase (Fig. 6A). Although the antibody recognizes both cFLIP-L and cFLIP-S, a splicing variant of cFLIP-L, cFLIP-S was not identified in the immunocomplexes. Taken together, these observations suggest that cFLIP-L, but not cFLIP-S binds the nonphosphorylated form of p38 MAPK. This binding interaction appears to prevent bile acid-associated p38 MAPK phosphorylation/activation.



View larger version (60K):
[in this window]
[in a new window]
 
FIG. 6.
cFLIP interacts directly with p38 MAPK. HuH7 cells were incubated with or without (Control) 100 µM DC for 4 h and lysed for immunoprecipitation using (A) anti-cFLIP and (B) anti-p38 MAPK antibodies. Western blot analysis of whole cell lysates and immunoprecipitates was performed using anti-phospho-p38 MAPK, anti-total p38 MAPK, and anti-cFLIP antibodies. Although cFLIP-L and p38 MAPK co-immunoprecipitated with each other, the active/phospho-p38 MAPK was not identified in the immunocomplexes. Data representative of at least three separate experiments are depicted.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The principal findings of this study relate MAPK activation and cFLIP cytoprotection during bile acid-mediated apoptosis. The results demonstrate that during deoxycholate-mediated apoptosis: (i) p42/44 MAPK, p38 MAPK, and JNK 1/2 are all activated, but only inhibition of p38 MAPK attenuates apoptosis; (ii) p38 MAPK activation does not appear to be death receptor-mediated; (iii) enhanced expression of cFLIP-L abrogates p38 MAPK activation; and (iv) p38 MAPK and cFLIP-L co-immunoprecipitate suggesting that these proteins are bound directly or indirectly in protein complexes. These data suggest that cFLIP-L may exert its anti-apoptotic activity, in part, by inhibiting p38 MAPK activation, likely by binding to and sequestering this MAPK; an additional anti-apoptotic effect for this protein during bile acid-mediated apoptosis.

Consistent with the observations of others, we observed activation of JNK 1/2, p42/44 MAPK, and p38 MAPK during exposure of HuH7 cells to deoxycholate. Although JNK 1/2 activation has been implicated in bile acid apoptosis by promoting trafficking of Fas to the plasma membrane (14), a pharmacologic JNK 1/2 inhibitor did not prevent deoxycholate-induced apoptosis in our studies. As HuH7 cells do not express Fas (8), this may be an explanation for the discrepancy between these prior studies and our current results. Moreover, others have suggested a role for bile acid-induced JNK 1/2 activation in regulating bile acid synthesis in the absence of cytotoxicity (45). These latter published results coupled with our current observations suggest that bile acid-mediated apoptosis is unlikely to be JNK 1/2-dependent. p42/44 MAPK inhibition also did not attenuate apoptosis consistent with the observations of others that activation of this MAPK leads to cell survival rather than cell death. Indeed, inhibition of p42/44 MAPK has been shown by some but not all to potentiate bile acid-mediated apoptosis suggesting that it may have a cytoprotective effect (4, 20, 46, 47). The contribution of p38 MAPK to bile acid-induced apoptosis has not been extensively studied. Our current study demonstrates that the activation of p38 MAPK is proapoptotic and contributes to apoptosis during treatment of cells with a cytotoxic bile acid, consistent with its proapoptotic functions in other models (21, 22, 48, 49). Of the four isoforms of p38 MAPK that have been cloned only p38-{alpha} and p38-{beta} are ubiquitously expressed, whereas p38-{gamma} is predominantly found in skeletal muscle and p38-{delta} is enriched in lung, kidney, testis, pancreas, and small intestine (5053); moreover SB203580, the inhibitor used in these studies, only inhibits p38-{alpha} and -{beta}, but not {gamma} and {delta} (54). Therefore we suggest that p38-{alpha} or -{beta} contribute to bile acid-mediated apoptosis.

p38 MAPK activation has previously been identified in death receptor signaling by Fas and TNF-R1. In Fas-directed activation of p38 MAPK, caspase 8 activation is required (55). However, caspase-8 activation is not necessary for p38 MAPK activation by TNF-R1 (56). In the current studies, we employed HuH7 cells that lack Fas but do express TRAIL-R1 and -R2, and TNF-R1. However, TRAIL treatment of the cells failed to elicit p38 MAPK phosphorylation. Although TNF-{alpha} treatment did result in p38 MAPK phosphorylation, TNF-R1 blocking antisera failed to prevent bile acid-induced p38 MAPK phosphorylation. A pancaspase inhibitor and siRNA directed knock down in FADD expression also did not alter bile acid activation of p38 MAPK. Collectively, these data make it unlikely that bile acid-associated p38 MAPK activation is death receptor-mediated, at least by FADD/caspase-dependent signaling processes, and suggest that combinatorial signaling events contribute to bile acid cytotoxicity.

Enhanced expression of cFLIP protected against bile acid-mediated apoptosis as reported previously by Qiao et al. (4). Cytoprotection by cFLIP has been attributed to abrogation of death receptor cytotoxic signaling (29, 38, 39). cFLIP-L is structurally similar to procaspase 8 in that it contains two death effector domains and a caspase-like domain. However, the caspase domain lacks the critical active site cysteine residue essential for catalytic activity. cFLIP-S, a splicing variant of cFLIP-L, lacks a portion of the caspase domain but contains the two DED domains (37). Both cFLIP isoforms bind to FADD within the DISC via DED-DED homotypic interactions and interfere with caspase 8 processing and activation (29, 57, 58). However, in our current studies we observed that cFLIP-L overexpression also inhibits p38 MAPK activation, which appears to occur by a FADD/caspase-independent mechanism. These intriguing data suggest that cFLIP-L also has cytoprotective effects independent of its interactions with death receptor membrane complexes. Indeed, in co-immunoprecipitation experiments in nontransfected cells, we were able to show a potential binding interaction between cFLIP-L and unphosphorylated p38 MAPK. Based on these observations, we postulate that in unstimulated cells cFLIP-L constitutively participates in a protein complex consisting of inactive p38 MAPK and perhaps additional proteins, rendering it inaccessible to phosphorylation by upstream kinases. Because cFLIP-S was not identified in the immunoprecipitation experiments, this effect of cFLIP appears to be specific to the long form, and suggests that the caspase domain of this protein is important for binding in this protein complex. Whether cFLIP-L directly or indirectly modulates p38 MAPK activation within protein complexes, its inhibition of the activation of this proapoptotic kinase appears to be an additional cytoprotective mechanism for this protein.

Toxic bile acids clearly promote hepatocyte apoptosis and injury in vivo. For example, children lacking the canalicular transport protein for bile salt secretion into the bile develop a progressive liver disease because of the inability to excrete bile salts from the hepatocyte (59). Mice with gene-targeted impairments in biliary secretion also develop hepatocyte apoptosis and liver injury when fed human bile acids (60, 61). The mechanisms of bile acid-mediated apoptosis are strikingly similar in vivo when compared with in vitro studies. Indeed, mechanisms of hepatocyte apoptosis occurring in bile duct-ligated animals parallel those observed in isolated cell systems (9). More pertinent to the current study, we have also observed MAPK p38 activation in the liver of 3-day bile duct-ligated mice. Thus, the results of this in vitro study appear to be quite germaine to the mechanisms of hepatocyte apoptosis in vivo during cholestatic liver syndromes.

Collectively, the current studies define a mechanistic proapoptotic function for p38 MAPK and expand the role of cFLIP cytoprotection in bile acid cytotoxicity, a cellular model for cholestatic liver injury. The data demonstrate that attenuation of p38 MAPK activation reduces apoptosis, whereas enhanced cFLIP-L expression is cytoprotective, in part, by reducing p38 MAPK phosphorylation/activation. If bile acid-associated p38 MAPK activation can be implicated in bile acid-mediated liver injury in vivo, perhaps p38 MAPK inhibitors may help alleviate human cholestatic liver injury. Likewise, mechanistic approaches that enhance cFLIP-L expression may also be therapeutically useful (62, 63). The implications of these studies for potential therapy of human cholestatic liver disease merits further investigation.


    FOOTNOTES
 
* This work was supported by National Institutes of Health Grant DK41876 and the Mayo and Palumbo Foundations. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed: Mayo Medical School, Clinic, and Foundation, 200 First St. SW, Rochester, MN 55905. Tel.: 507-284-0686; Fax: 507-284-0762; E-mail: gores.gregory{at}mayo.edu.

1 The abbreviations used are: MAPK, mitogen-activated protein kinase; cFLIP, cellular FLICE inhibitory protein; DAPI, 4',6-diamidino-2-phenylindole dihydrochloride; DC, deoxycholate; DED, death effector domain; DISC, death inducing signaling complex; DR, death receptor; FADD, Fas-associated death domain protein; FAM-VAD-fmk, carboxyfluorescein-VAD-fmk; GFP, green fluorescent protein; JNK, c-Jun NH2-terminal kinase; MKK, mitogen-activated protein kinase kinase; siRNA, short interfering RNA; TNF-{alpha}, tumor necrosis factor-{alpha}; TNF-R1, tumor necrosis factor receptor 1; TRAIL, tumor necrosis factor-related apoptosis inducing ligand; TRAIL-R, tumor necrosis factor-related apoptosis inducing ligand-receptor. Back

2 www.ambion.com. Back


    ACKNOWLEDGMENTS
 
The secretarial services of Erin Bungum are gratefully acknowledged.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Rust, C., and Gores, G. J. (2000) Am. J. Med. 108, 567–574[CrossRef][Medline] [Order article via Infotrieve]
  2. Greim, H., Trulzsch, D., Czygan, P., Rudick, J., Hutterer, F., Schaffner, F., and Popper, H. (1972) Gastroenterology 63, 846–850[Medline] [Order article via Infotrieve]
  3. Rodrigues, C. M., Fan, G., Ma, X., Kren, B. T., and Steer, C. J. (1998) J. Clin. Invest. 101, 2790–2799[Abstract/Free Full Text]
  4. Qiao, L., Studer, E., Leach, K., McKinstry, R., Gupta, S., Decker, R., Kukreja, R., Valerie, K., Nagarkatti, P., El Deiry, W., Molkentin, J., Schmidt-Ullrich, R., Fisher, P. B., Grant, S., Hylemon, P. B., and Dent, P. (2001) Mol. Biol. Cell 12, 2629–2645[Abstract/Free Full Text]
  5. Webster, C. R., and Anwer, M. S. (1998) Hepatology 27, 1324–1331[Medline] [Order article via Infotrieve]
  6. Gumpricht, E., Dahl, R., Yerushalmi, B., Devereaux, M. W., and Sokol, R. J. (2002) J. Biol. Chem. 277, 25823–25830[Abstract/Free Full Text]
  7. Faubion, W. A., Guicciardi, M. E., Miyoshi, H., Bronk, S. F., Roberts, P. J., Svingen, P. A., Kaufmann, S. H., and Gores, G. J. (1999) J. Clin. Invest. 103, 137–145[Abstract/Free Full Text]
  8. Higuchi, H., Bronk, S. F., Takikawa, Y., Werneburg, N., Takimoto, R., El-Deiry, W., and Gores, G. J. (2001) J. Biol. Chem. 276, 38610–38618[Abstract/Free Full Text]
  9. Miyoshi, H., Rust, C., Roberts, P. J., Burgart, L. J., and Gores, G. J. (1999) Gastroenterology 117, 669–677[Medline] [Order article via Infotrieve]
  10. Canbay, A., Higuchi, H., Bronk, S. F., Taniai, M., Sebo, T. J., and Gores, G. J. (2002) Gastroenterology 123, 1323–1330[CrossRef][Medline] [Order article via Infotrieve]
  11. Higuchi, H., Bronk, S. F., Taniai, M., Canbay, A., and Gores, G. J. (2002) J. Pharmacol. Exp. Ther. 303, 461–467[Abstract/Free Full Text]
  12. Kurz, A. K., Graf, D., Schmitt, M., Vom Dahl, S., and Haussinger, D. (2001) Gastroenterology 121, 407–419[Medline] [Order article via Infotrieve]
  13. Schliess, F., Kurz, A. K., vom Dahl, S., and Haussinger, D. (1997) Gastroenterology 113, 1306–1314[Medline] [Order article via Infotrieve]
  14. Graf, D., Kurz, A. K., Fischer, R., Reinehr, R., and Haussinger, D. (2002) Gastroenterology 122, 1411–1427[Medline] [Order article via Infotrieve]
  15. Sluss, H. K., Barrett, T., Derijard, B., and Davis, R. J. (1994) Mol. Cell. Biol. 14, 8376–8384[Abstract]
  16. Juo, P., Kuo, C. J., Reynolds, S. E., Konz, R. F., Raingeaud, J., Davis, R. J., Biemann, H. P., and Blenis, J. (1997) Mol. Cell. Biol. 17, 24–35[Abstract]
  17. Cardier, J. E., and Erickson-Miller, C. L. (2002) Microvasc. Res. 63, 10–18[CrossRef][Medline] [Order article via Infotrieve]
  18. Tran, S. E., Holmstrom, T. H., Ahonen, M., Kahari, V. M., and Eriksson, J. E. (2001) J. Biol. Chem. 276, 16484–16490[Abstract/Free Full Text]
  19. Muhlenbeck, F., Haas, E., Schwenzer, R., Schubert, G., Grell, M., Smith, C., Scheurich, P., and Wajant, H. (1998) J. Biol. Chem. 273, 33091–33098[Abstract/Free Full Text]
  20. Qiao, D., Stratagouleas, E. D., and Martinez, J. D. (2001) Carcinogenesis 22, 35–41[Abstract/Free Full Text]
  21. Kummer, J. L., Rao, P. K., and Heidenreich, K. A. (1997) J. Biol. Chem. 272, 20490–20494[Abstract/Free Full Text]
  22. Xia, Z., Dickens, M., Raingeaud, J., Davis, R. J., and Greenberg, M. E. (1995) Science 270, 1326–1331[Abstract]
  23. Hagemann, C., and Blank, J. L. (2001) Cell Signalling 13, 863–875[CrossRef][Medline] [Order article via Infotrieve]
  24. Strasser, A., and Newton, K. (1999) Int. J. Biochem. Cell Biol. 31, 533–537[CrossRef][Medline] [Order article via Infotrieve]
  25. Bodmer, J. L., Holler, N., Reynard, S., Vinciguerra, P., Schneider, P., Juo, P., Blenis, J., and Tschopp, J. (2000) Nat. Cell Biol. 2, 241–243[CrossRef][Medline] [Order article via Infotrieve]
  26. Kischkel, F. C., Lawrence, D. A., Tinel, A., LeBlanc, H., Virmani, A., Schow, P., Gazdar, A., Blenis, J., Arnott, D., and Ashkenazi, A. (2001) J. Biol. Chem. 276, 46639–46646[Abstract/Free Full Text]
  27. Thornberry, N. A., and Lazebnik, Y. (1998) Science 281, 1312–1316[Abstract/Free Full Text]
  28. Shi, Y. (2002) Mol. Cell 9, 459–470[Medline] [Order article via Infotrieve]
  29. Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J. L., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., and Tschopp, J. (1997) Nature 388, 190–195[CrossRef][Medline] [Order article via Infotrieve]
  30. Srinivasula, S. M., Ahmad, M., Ottilie, S., Bullrich, F., Banks, S., Wang, Y., Fernandes-Alnemri, T., Croce, C. M., Litwack, G., Tomaselli, K. J., Armstrong, R. C., and Alnemri, E. S. (1997) J. Biol. Chem. 272, 18542–18545[Abstract/Free Full Text]
  31. Hu, S., Vincenz, C., Ni, J., Gentz, R., and Dixit, V. M. (1997) J. Biol. Chem. 272, 17255–17257[Abstract/Free Full Text]
  32. Shu, H. B., Halpin, D. R., and Goeddel, D. V. (1997) Immunity 6, 751–763[Medline] [Order article via Infotrieve]
  33. Goltsev, Y. V., Kovalenko, A. V., Arnold, E., Varfolomeev, E. E., Brodianskii, V. M., and Wallach, D. (1997) J. Biol. Chem. 272, 19641–19644[Abstract/Free Full Text]
  34. Han, D. K., Chaudhary, P. M., Wright, M. E., Friedman, C., Trask, B. J., Riedel, R. T., Baskin, D. G., Schwartz, S. M., and Hood, L. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 11333–11338[Abstract/Free Full Text]
  35. Inohara, N., Koseki, T., Hu, Y., Chen, S., and Nunez, G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10717–10722[Abstract/Free Full Text]
  36. Rasper, D. M., Vaillancourt, J. P., Hadano, S., Houtzager, V. M., Seiden, I., Keen, S. L., Tawa, P., Xanthoudakis, S., Nasir, J., Martindale, D., Koop, B. F., Peterson, E. P., Thornberry, N. A., Huang, J., MacPherson, D. P., Black, S. C., Hornung, F., Lenardo, M. J., Hayden, M. R., Roy, S., and Nicholson, D. W. (1998) Cell Death Differ. 5, 271–288[CrossRef][Medline] [Order article via Infotrieve]
  37. Krueger, A., Baumann, S., Krammer, P. H., and Kirchhoff, S. (2001) Mol. Cell. Biol. 21, 8247–8254[Free Full Text]
  38. Burns, T. F., and El-Deiry, W. S. (2001) J. Biol. Chem. 276, 37879–37886[Abstract/Free Full Text]
  39. Thome, M., and Tschopp, J. (2001) Nat. Rev. Immunol. 1, 50–58[CrossRef][Medline] [Order article via Infotrieve]
  40. Schlottman, K., Wachs, F. P., Krieg, R. C., Kullmann, F., Scholmerich, J., and Rogler, G. (2000) Cancer Res. 60, 4270–4276[Abstract/Free Full Text]
  41. Raingeaud, J., Whitmarsh, A. J., Barrett, T., Derijard, B., and Davis, R. J. (1996) Mol. Cell. Biol. 16, 1247–1255[Abstract]
  42. Derijard, B., Raingeaud, J., Barrett, T., Wu, I. H., Han, J., Ulevitch, R. J., and Davis, R. J. (1995) Science 267, 682–685[Medline] [Order article via Infotrieve]
  43. Shima, Y., Nakao, K., Nakashima, T., Kawakami, A., Nakata, K., Hamasaki, K., Kato, Y., Eguchi, K., and Ishii, N. (1999) Hepatology 30, 1215–1222[Medline] [Order article via Infotrieve]
  44. Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. (1997) J. Clin. Invest. 99, 403–413[Abstract/Free Full Text]
  45. Gupta, S., Stravitz, R. T., Dent, P., and Hylemon, P. B. (2001) J. Biol. Chem. 276, 15816–15822[Abstract/Free Full Text]
  46. Webster, C. R., and Anwer, M. S. (2001) Hepatology 33, 608–615[CrossRef][Medline] [Order article via Infotrieve]
  47. Qiao, L., Yacoub, A., Studer, E., Gupta, S., Pei, X. Y., Grant, S., Hylemon, P. B., and Dent, P. (2002) Hepatology 35, 779–789[CrossRef][Medline] [Order article via Infotrieve]
  48. Saldeen, J., Lee, J. C., and Welsh, N. (2001) Biochem. Pharmacol. 61, 1561–1569[CrossRef][Medline] [Order article via Infotrieve]
  49. Tobiume, K., Matsuzawa, A., Takahashi, T., Nishitoh, H., Morita, K., Takeda, K., Minowa, O., Miyazono, K., Noda, T., and Ichijo, H. (2001) EMBO Rep. 2, 222–228[Abstract/Free Full Text]
  50. Jiang, Y., Chen, C., Li, Z., Guo, W., Gegner, J. A., Lin, S., and Han, J. (1996) J. Biol. Chem. 271, 17920–17926[Abstract/Free Full Text]
  51. Li, Z., Jiang, Y., Ulevitch, R. J., and Han, J. (1996) Biochem. Biophys. Res. Commun. 228, 334–340[CrossRef][Medline] [Order article via Infotrieve]
  52. Lechner, C., Zahalka, M. A., Giot, J. F., Moller, N. P., and Ullrich, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4355–4359[Abstract/Free Full Text]
  53. Kumar, S., McDonnell, P. C., Gum, R. J., Hand, A. T., Lee, J. C., and Young, P. R. (1997) Biochem. Biophys. Res. Commun. 235, 533–538[CrossRef][Medline] [Order article via Infotrieve]
  54. Tong, L., Pav, S., White, D. M., Rogers, S., Crane, K. M., Cywin, C. L., Brown, M. L., and Pargellis, C. A. (1997) Nat. Struct. Biol. 4, 311–316[Medline] [Order article via Infotrieve]
  55. Cahill, M. A., Peter, M. E., Kischkel, F. C., Chinnaiyan, A. M., Dixit, V. M., Krammer, P. H., and Nordheim, A. (1996) Oncogene 13, 2087–2096[Medline] [Order article via Infotrieve]
  56. Newton, K., Kurts, C., Harris, A. W., and Strasser, A. (2001) Curr. Biol. 11, 273–276[CrossRef][Medline] [Order article via Infotrieve]
  57. Krueger, A., Schmitz, I., Baumann, S., Krammer, P. H., and Kirchhoff, S. (2001) J. Biol. Chem. 276, 20633–20640[Abstract/Free Full Text]
  58. Scaffidi, C., Schmitz, I., Krammer, P. H., and Peter, M. E. (1999) J. Biol. Chem. 274, 1541–1548[Abstract/Free Full Text]
  59. Thompson, R., and Jansen, P. L. (2000) Semin. Liver Dis. 20, 365–372[CrossRef][Medline] [Order article via Infotrieve]
  60. De Vree, J. M., Ottenhoff, R., Bosma, P. J., Smith, A. J., Aten, J., and Oude Elferink, R. P. (2000) Gastroenterology 119, 1720–1730[Medline] [Order article via Infotrieve]
  61. Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., and Gonzalez, F. J. (2000) Cell 102, 731–744[Medline] [Order article via Infotrieve]
  62. Bartke, T., Siegmund, D., Peters, N., Reichwein, M., Henkler, F., Scheurich, P., and Wajant, H. (2001) Oncogene 20, 571–580[CrossRef][Medline] [Order article via Infotrieve]
  63. Bortul, R., Tazzari, P. L., Cappellini, A., Tabellini, G., Billi, A. M., Bareggi, R., Manzoli, L., Cocco, L., and Martelli, A. M. (2003) Leukemia 17, 379–389[CrossRef][Medline] [Order article via Infotrieve]